Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Nyberg, S. Articles by Farde, L. Search for Related Content PubMed Citation Articles by Nyberg, S. Articles by Farde, L. Schizophrenia Spectrum Disorders Other Neuroleptics PET

Suggested Minimal Effective Dose of Risperidone Based on PET-Measured D₂ and 5-HT_2A Receptor Occupancy in Schizophrenic Patients

OBJECTIVE: Multicenter trials with the novel antipsychotic risperidone have suggested a standard dose of 6 mg/day. However, a dose producing the highest response rate in fixed-dose studies is likely to exceed the minimal effective dose in most patients. The aim of this positron emission tomography (PET) study was to suggest a minimal effective dose of risperidone based on measurements of dopamine D₂ and serotonin 5-HT_2A receptor occupancy. METHOD: Eight first-episode or drug-free schizophrenic patients were treated with risperidone, 6 mg/day, for 4 weeks and then 3 mg/day for 2 weeks. PET was performed after 4 and 6 weeks, with [¹¹C]raclopride to measure D₂ receptor occupancy and [¹¹C]N-methyl­spiperone to measure 5-HT_2A receptor occupancy. RESULTS: Seven patients completed the study and responded to treatment with risperidone. No patient had extrapyramidal side effects at the time of inclusion in the study. At the 6-mg/day dose, mean D₂ receptor occupancy was 82% (range=79%–85%), 5-HT_2A receptor occupancy was 95% (range=86%–109%), and six patients had developed extrapyramidal side effects. After dose reduction to 3 mg/day, D₂ receptor occupancy was 72% (range=53%–78%), and 5-HT_2A receptor occupancy was 83% (range=65%–112%). Three patients had extrapyramidal side effects at this time. CONCLUSIONS: Treatment with risperidone, 6 mg/day, is likely to induce unnecessarily high D₂ receptor occupancy, with a consequent risk of extrapyramidal side effects. High 5-HT_2A receptor occupancy did not prevent extrapyramidal side effects completely. The authors previously suggested an optimal interval for D₂ receptor occupancy of 70%–80%. To achieve this, risperidone, 4 mg/day, should be a suitable initial dose for antipsychotic effect with a minimal risk of extrapyramidal side effects in most patients.

This article has been cited by other articles:

				N. Ezewuzie and D. Taylor Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia J Psychopharmacol, January 1, 2006; 20(1): 86 - 90. [Abstract] [PDF]

				N. R. Pinninti and R. Mago Use of Long-Acting Risperidone Psychiatr Serv, January 1, 2005; 56(1): 105 - 105. [Full Text] [PDF]

				N. Santana, A. Bortolozzi, J. Serrats, G. Mengod, and F. Artigas Expression of Serotonin1A and Serotonin2A Receptors in Pyramidal and GABAergic Neurons of the Rat Prefrontal Cortex Cereb Cortex, October 1, 2004; 14(10): 1100 - 1109. [Abstract] [Full Text] [PDF]

				R. M. Moresco, R. Cavallaro, C. Messa, D. Bravi, C. Gobbo, L. Galli, G. Lucignani, C. Colombo, G. Rizzo, I. Velona, et al. Cerebral D2 and 5-HT2 Receptor occupancy in Schizophrenic Patients Treated with Olanzapine Or Clozapine J Psychopharmacol, September 1, 2004; 18(3): 355 - 365. [Abstract] [PDF]

				G. Grunder, A. Carlsson, and D. F. Wong Mechanism of New Antipsychotic Medications: Occupancy Is Not Just Antagonism Arch Gen Psychiatry, October 1, 2003; 60(10): 974 - 977. [Abstract] [Full Text] [PDF]

				S. Ahmed, P. D. Mozley, and W. Z. Potter Biomarkers in Psychotropic Drug Development Am J Geriatr Psychiatry, December 1, 2002; 10(6): 678 - 686. [Abstract] [Full Text] [PDF]

				L. de HAAN and T. van AMELSVOORT Comparable Dopamine 2 Receptor Occupancy Am J Psychiatry, December 1, 2002; 159(12): 2118 - 2118. [Full Text]

				X. XIBERAS, J. L. MARTINOT, L. MALLET, E. ARTIGES, C. LOC'H, B. MAZIERE, and M. L. PAILLERE-MARTINOT Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia The British Journal of Psychiatry, December 1, 2001; 179(6): 503 - 508. [Abstract] [Full Text] [PDF]

				D. J. Lang, L. C. Kopala, R. A. Vandorpe, Q. Rui, G. N. Smith, V. M. Goghari, and W. G. Honer An MRI Study of Basal Ganglia Volumes in First-Episode Schizophrenia Patients Treated With Risperidone Am J Psychiatry, April 1, 2001; 158(4): 625 - 631. [Abstract] [Full Text]

				J. Windhaber, S. Urbanits, W. Grisold, M. F. Mazurek, and P. I. Rosebush Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone Neurology, April 11, 2000; 54(7): 1542 - 1546. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us